ClinicalTrials.gg
RecruitingNCT04604782Rapiscan PIPUpdated May 6, 2026

A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients

A Phase 1/2 interventional study of Regadenoson in Myocardial Ischemia and Coronary Artery Disease, sponsored by GE Healthcare. Recruiting at 5 sites in 4 countries. Open to participants aged 4 Weeks to 18 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Primary conditionCoronary Artery DiseaseRegistry: Myocardial IschemiaReclassifiedWhy we changed it
Registry
Myocardial Ischemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Coronary Artery Disease
Why
  1. The study's listed conditions name Coronary Artery Disease, a narrower term within Myocardial Ischemia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GE Healthcare · Phase 1/2, Interventional, and Diagnostic

From the registry’s dates

  • Started May 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
4 Weeks to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 23 studies testing regadenoson in Coronary Artery Disease — 1 open to participants now, 1 under way, none of them phase 3. regadenoson · Coronary Artery Disease.

Planned enrollment
11th of 23
54 · median 50
Started
2021
with 1 other
Phase 1/2
Only one
of the 23
Registered
23rd of 23
by date
Lead sponsor
1 of 23
GE Healthcare

Among the 23 studies testing regadenoson in Coronary Artery Disease, this one is the 11th largest by planned enrollment, is one of 2 that started in 2021, is the only one in phase 1/2, and was the 23rd registered.

Coronary Artery Disease

4,865 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 23 studies testing regadenoson in Coronary Artery Disease is open now, in 4 countries.

By country, each count listing its studies:

About regadenoson

regadenoson: first FDA approval 2008 (LEXISCAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 4 Weeks to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing regadenoson in Coronary Artery Disease, or all of them as a file.
02

Study summary

This is a multi-centre, open-label, single-dose safety, tolerability and PK-pharmacodynamics (PD) study of the vasodilator regadenoson in 3 paediatric age groups for whom a pharmacologic stress perfusion CMR test is clinically indicated; adolescents aged 12 to \<18 years (Cohort A), children aged 2 to \<12 years (Cohort B), and infants aged 1 to \<24 months and who weigh at least 3 kg (Cohort C). Regadenoson will be used as the pharmacologic stress agent in this study with MPI serving as both surrogate pharmacodynamic marker of the agent (MPR, MBF) and a clinically evaluable examination for the patient

Read the detailed description

This is a multi-centre, open-label, single-dose safety, tolerability and PK-pharmacodynamics (PD) study of the vasodilator regadenoson in 3 paediatric age groups for whom a pharmacologic stress perfusion CMR test is clinically indicated; adolescents aged 12 to \<18 years (Cohort A), children aged 2 to \<12 years (Cohort B), and infants aged 1 to \<24 months and who weigh at least 3 kg (Cohort C). Regadenoson will be used as the pharmacologic stress agent in this study with MPI serving as both surrogate pharmacodynamic marker of the agent (MPR, MBF) and a clinically evaluable examination for the patient.

At least 54 paediatric patients will be enrolled at approximately 10 centres in Europe: at least 24 adolescents aged 12 to \<18 years (Cohort A), at least 18 children aged 2 to \<12 years (Cohort B), and at least 12 infants aged 1 to \<24 months (Cohort C). The study will be conducted in facilities appropriate for children, and by personnel knowledgeable and skilled in working with paediatric patients. Every attempt will be made to minimise the discomfort of the procedures to the patients. General anaesthesia/sedation with no oral-intake instructions may be used in accordance with age / disease specific requirements of the patient and as deemed necessary by the investigator per standard of care / local practice. In addition, adequate resuscitation equipment and personnel trained and certified in advanced life support must be readily available when regadenoson is administered. A Data Safety Monitoring Board (DSMB) will be in place, and will formally review all safety, efficacy, PK and PD information during the conduct of the study to ensure the safety of patients.

The study will be performed in a sequential manner across the 3 age groups, by decreasing age from adolescents (Cohort A) to children (Cohort B) and to infants (Cohort C). Dosing recommendations for the paediatric population are based on effective dose levels and PK data in adults. Based on a fixed dose of 400 µg regadenoson administered to adults with a mean body weight of 83.8 kg (body weight range: 42 to 161 kg), the effective mean weight-based dose was 4.8 µg/kg (range: 2.5 to 9.5 µg/kg). Within each age group, dosing will be extrapolated from PK-PD data obtained in adults and will be based on body weight-categories to provide approximately the same exposure as 400 µg in adults. The study will start with Cohort A (adolescents). Before the start of dosing in Cohort B, all safety, PK, and PD data obtained in Cohort A will be reviewed by the DSMB. Before the start of dosing in Cohort C, all safety, PK, and PD data obtained in Cohorts A and B will be reviewed by the DSMB.

03

Conditions studied

  • Myocardial Ischemia
  • Coronary Artery Disease

Browse trials for

04

In context

Coronary Artery Disease Reclassified

4,865 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

This study's planned enrollment of 54 is below the median of 123 across 3,012 interventional studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

GE Healthcare is the lead sponsor of 176 studies on the registry; 21 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.

Compared within Coronary Artery Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myocardial Ischemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
4 Weeks to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • * Male or female adolescent aged from 12 to \<18 years (Cohort A) or child aged from 2 to \<12 years (Cohort B) or infant aged from 1 to \<24 months (Cohort C).

    • Patient weighs at least 3 kg.
    • Patients who need to undergo a clinically indicated pharmacologic stress perfusion CMR test and who are considered fit for a pharmacological stress perfusion CMR by the investigator. The pharmacologic stress perfusion CMR may be performed in patients for further evaluation of cardiovascular conditions or diseases, such as, but not limited to, Kawasaki disease, congenital heart diseases, congenital coronary abnormalities, and post-cardiac surgery / transplantation, etc.
    • Stable medication regimen for at least 7 days prior to dosing. Stable is defined as no addition, discontinuation, or change of any medications (or their doses), that could alter the rate-pressure product (HR x BP).
    • Patients and those whose parents or legally authorised representatives are, in the Investigator's view, likely to be compliant and complete the study will be eligible to participate
    • Post-menarchal female patients must have a negative urine pregnancy test at screening and at pre-dose on the dosing day.
    • Post-menarchal female patients must be practicing abstinence, or be using an effective form of (e.g., intrauterine device, oral contraceptives, contraceptive implants or injections, diaphragm with spermicide, cervical cap, or consort use of condom) for at least 30 days before being enrolled in the study

Exclusion criteria

Exclusion Criteria:

  • * Prior allergic reaction to Gd contrast agents and/or regadenoson or any component of its formulation, or to aminophylline or to its components (ethylenediamine and theophylline).

    • Standard clinical to MRI as per institutional guidance, including patients with cochlear implants and implanted cardiac devices, or considered unfit for a pharmacologic stress perfusion CMR test by the investigator.
    • All patients will be screened for within 24 hours before the exam and patients presenting with eGFR \<30 mL/min/1.73 m2 (by the Schwartz formula) will be excluded.
    • Pregnant or lactating females, or females of not using an acceptable form of (negative urine pregnancy test also required).
    • In the judgment of the Investigator, any ongoing medical condition (e.g., myocardial infarction, or unstable angina within 5 days, pericardial inflammatory disease, severe cardiac outflow tract obstruction, acutely decompensated heart failure, uncontrolled epilepsy, high risk for seizures, etc.) or clinically significant laboratory abnormality that is considered to potentially jeopardise the patient's safety.
    • Patients with 2nd or 3rd degree atrioventricular block or sick sinus syndrome with or without an artificial pacemaker.
    • Known or suspected bronchoconstrictive and bronchospastic lung disease either being unstable or requiring active treatment (e.g., wheezing noted on physical exam, frequent exacerbations or active treatment with a bronchodilator or ).
    • Out of acceptable range sitting or semi-recumbent resting BP or HR (beats per minute [bpm]) at screening as provided below:

      1. Acceptable range for BP (systolic / diastolic mmHg):
  • For Cohorts A and B: 85-130 / 45-90
  • For Cohort C: 80-120 / 40-80 b) Acceptable range for HR:
  • For Cohort A: 55 to 100 bpm
  • For Cohort B: 60 to 120 bpm
  • For Cohort C: 70 to 160 bpm

    • Use of any experimental or drug or device within 30 days prior to dosing with study drug
    • Consumption of methylxanthine-containing products such as caffeinated coffee, tea, caffeinated soft drinks, cocoa or chocolate in the 48 hours prior to dosing
    • Aminophylline or theophylline use within 24 hours, dipyridamole use within 48 hours prior to dosing.
    • History of alcohol abuse or drug addiction, as determined by the Investigator
    • Currently smokes more than 5 cigarettes or equivalent per day, and if eligible for the study, would not be able to abstain from smoking from midnight prior to dosing until the end of the study period
    • Positive urine drug screen at the screening visit, including amphetamines, barbiturates, cannabinoids, cocaine, ethanol and opiates. This will be performed for all patients in Cohort A and those patients at age-appropriate risk in Cohorts B and C, as determined by the investigator.

Note: If the patient is currently receiving prescribed medications containing any of these ingredients, re-screening can only be considered if found acceptable based on the best medical judgement of the investigator and after discussion with the medical monitor. Otherwise, patients with a positive urine drug test will be considered a screen failure.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    adolescents aged 12 to <18 years

    Drug: Regadenoson

  • Experimental
    children aged 2 to <12 years

    Drug: Regadenoson

  • Experimental
    infants aged 1 to <24 months and who weigh at least 3 kg

    Drug: Regadenoson

Interventions

  • Regadenoson (Rapiscan®): Single i.v. bolus dose in stress rest CMR

    Also known as: Rapiscan

07

What researchers measure

Primary outcomes

  1. Occurrence of Adverse Events (AEs) following administration of Regadenoson

    An overall summary of AEs, SAEs, and Regadenoson-emergent AEs will be presented, coded using the Medical Dictionary for Regulatory Activities (MedDRA) and summarized by system organ class and preferred term.

    Time frame: 70 hours after Regadenoson administration

  2. Changes in physical examinations following administration of Regadenoson

    The number of patients with changes in physical examination status from normal at baseline to abnormal at each post-administration time point will be summarized.

    Time frame: Baseline and 2 hours after Regadenoson administration

  3. Changes in physical examinations following administration of Regadenoson

    The percentage of patients with changes in physical examination status from normal at baseline to abnormal at each post-administration time point will be summarized.

    Time frame: Baseline and 2 hours after Regadenoson administration

  4. Changes in oxygen saturation following administration of Regadenoson

    The occurrence of post-administration vital sign values outside the normal limits will be summarized.

    Time frame: Baseline, 15 and 5 minutes before Regadenoson administration and 1, 3, 6, 10, 15, 30 minutes and 1, 2 hours after Regadenoson administration

  5. Changes in blood pressure in mmHg following administration of Regadenoson

    The occurrence of post-administration vital sign values outside the normal limits will be summarized.

    Time frame: Baseline, 15 and 5 minutes before Regadenoson administration and 1, 3, 6, 10, 15, 30 minutes and 1, 2 hours after Regadenoson administration

  6. Changes in heart rate as bpm following administration of Regadenoson

    The occurrence of post-administration vital sign values outside the normal limits will be summarized.

    Time frame: Baseline, 15 and 5 minutes before Regadenoson administration and 1, 3, 6, 10, 15, 30 minutes and 1, 2 hours after Regadenoson administration

  7. Changes in body temperature (as degree C) following administration of Regadenoson

    The occurrence of post-administration body temperature values outside the normal limits will be summarized by counts and percentages by age group and actual dose.

    Time frame: Baseline and 2 hours after Regadenoson administration

  8. Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of Regadenoson

    Descriptive statistics will be used to describe the observed values and change from baseline for ECG intervals (RR, QT, QTcF\[Fridericia\])

    Time frame: Baseline, 1 and 2 hours after Regadenoson administration

  9. Changes in serum chemistry following administration of regadenoson

    The occurrence of post-administration clinical laboratory values outside the normal limits will be summarized.

    Time frame: Baseline and 2 hours after Regadenoson administration

  10. Time changes of regadenoson blood concentrations (ng/mL) with a single, body-weight adjusted i.v. dose in 3 paediatric populations: adolescents 12 to <18 years,children 2 to <12 years, and infants 1 to <24 months, and who weigh at least 3kg.

    Blood samples for PK assessment will be collected and processed for measurement of Regadenoson blood concentrations. Concentration-time profiles will be evaluated using compartmental methods and a population approach with mixed-effect modelling. A summary will be listed by patient and summarized by age group and actual dose at each time point.

    Time frame: 1, 3, 5, 10, and 20 minutes and 1 and 2 hours post Regadenoson administration

Secondary outcomes

  1. Determine the correlation between regadenoson PK concentration (ng/mL) and changes in HR (bpm), including impact of patient factors.

    The correlation between regadenoson PK concentration and change in HR at different time points will be evaluated using compartment methods and a population approach with mixed-effect modelling adjusted for patient factors.

    Time frame: 1, 3, 5, 10, and 20 minutes and 1 and 2 hours post Regadenoson administration

  2. Determine the associated myocardial hyperaemic response after administration of regadenoson using dynamic first-pass perfusion magnetic resonance imaging (MRI).

    The Myocardial perfusion reserve (MPR) and Myocardial blood flow (MBF) values derived from the quantitative image analysis of the myocardial perfusion images will be listed per patient and summarized with descriptive statistics by age group and actual dose.

    Time frame: 1 hour post Regadenoson administration.

  3. Determine the associated myocardial hyperaemic response after administration of regadenoson using dynamic first-pass quantitative myocardial perfusion reserve (MPR) analysis.

    The Myocardial perfusion reserve (MPR) and Myocardial blood flow (MBF) values derived from the quantitative image analysis of the myocardial perfusion images will be listed per patient and summarized with descriptive statistics by age group and actual dose.

    Time frame: 1 hour post Regadenoson administration.

08

Study locations

2 of 5 sites recruiting
  • Paris Public Hospitals System; Necker Hospital for Sick Children
    Paris, 75015, France
    Terminated

    Not enrolling at this site.

  • Mitera Hospital
    Athens, 15123, Greece
    Completed

    Not enrolling at this site.

  • Bambino Gesu Children Hospital
    Roma, 00165, Italy
    Recruiting
  • Bristol Royal Hospital for Children
    Bristol, BS28BJ, United Kingdom
    Not yet recruiting
  • King's College London, Rayne Institute
    London, SE1 7EH, United Kingdom
    Recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2021 (actual). Primary completion is estimated for Dec 2026, 67 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2020
First posted
Oct 27, 2020
StartActual
May 20, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04604782
Lead sponsor
GE Healthcare
Collaborators
Covance
Responsible party
Sponsor
First posted
Oct 27, 2020
Start date
May 20, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 6, 2026

Study contacts

Michelle Straszacker
Contact
michelle.straszacker@gehealthcare.com
+44 (0) 7827845147
David Thompson, MD, PhD
study director · GE Healthcare

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regadenoson

Start the discussion